CD274 and small cell lung carcinoma: The same product is under assessment in combination with Pembrolizumab or Nivolumab (anti-PD-1 mAbs), Durvalumab, Atezolizumab or Avelumab (anti-PD-L1 mAbs) for the treatment of several solid malignancies (including NSCLC, small-cell lung cancer (SCLC), urothelial carcinoma, HNSCC, MCC, melanoma, RCC, gastric cancer, cervical cancer, HCC, and CRC) in the Phase II QUILT-3.055 study (NCT03228667, Additional file 2: Table S2, row 42; Additional file 4: Table S4, row 34).